| Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures | | |
| Assessment of drug–drug interaction potential with EDP ‐305, a farnesoid X receptor agonist, in healthy subjects | Clinical and Translational Science | |
| Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib | Frontiers in Pharmacology | 2021 |
| PET Imaging of ABC Transporters at the Blood-Brain Barrier | | 2021 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2020 |
| Effect of Food on the Pharmacokinetics of Gliclazide 60 mg Modified Release Tablet in Healthy Caucasian Volunteers | Acta Marisiensis - Seria Medica | 2018 |
| Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development | | 2018 |
| Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in Japan | Japanese Journal of Clinical Pharmacology and Therapeutics | 2015 |
| Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro CYP Induction Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 | Methods in Pharmacology and Toxicology | 2014 |
| Membrane Transporters in ADME | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| In Vitro Kinetic Characterization of Transporter-Mediated Permeability | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions | Clinical Pharmacology and Therapeutics | 2021 |
| Drug-transporter interaction testing in drug discovery and development | World Journal of Pharmacology | 2013 |
| Irreversible enzyme inhibition kinetics and drug-drug interactions | Methods in Molecular Biology | 2014 |
| Reversible mechanisms of enzyme inhibition and resulting clinical significance | Methods in Molecular Biology | 2014 |
| Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation | Diabetes Therapy | 2021 |
| Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study | Clinical and Translational Science | 2021 |
| Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes | Clinical Pharmacology and Therapeutics | 2020 |
| The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam | Clinical Pharmacology and Therapeutics | 2020 |
| Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin | Clinical and Translational Science | 2020 |
| Test-Retest Repeatability of [F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function | ACS Chemical Neuroscience | 2020 |
| Drug Interactions in the Liver | | 2020 |
| Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects | Journal of Clinical Pharmacology | 2020 |
| Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor | Xenobiotica | 2020 |
| Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells | Biochemical Pharmacology | 2020 |
| Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine | Clinical Pharmacokinetics | 2020 |
| Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole) | Journal of Clinical Pharmacology | 2020 |
| Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity | Journal of Pharmacokinetics and Pharmacodynamics | 2020 |
| Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology | International Journal of Molecular Sciences | 2020 |
| Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary | European Journal of Pharmaceutics and Biopharmaceutics | 2020 |
| Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension | AAPS Journal | 2020 |
| Drug–Drug Interaction Studies | | 2020 |
| Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist | Journal of Clinical Pharmacology | 2020 |
| Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6 | Pharmacology Research and Perspectives | 2020 |
| Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions | AAPS Journal | 2020 |
| On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food | AAPS Journal | 2019 |
| Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment | Xenobiotica | 2020 |
| Simplified Method to Determine the Efflux Ratio on P-Glycoprotein Substrates Using Three-Compartment Model Analysis for Caco-2 Cell Assay Data | Pharmaceutical Research | 2019 |
| Effect of Food on the Pharmacokinetics of Quizartinib | Clinical Pharmacology in Drug Development | 2020 |
| Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model | Xenobiotica | 2019 |
| Absorption, disposition, metabolism and excretion of [C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats | Xenobiotica | 2019 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans | Clinical and Translational Science | 2019 |
| Management of Diabetes Mellitus | Contemporary Cardiology | 2019 |
| Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in Mice | Molecular Imaging and Biology | 2019 |
| In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel | European Journal of Drug Metabolism and Pharmacokinetics | 2019 |
| No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects | Clinical Pharmacology in Drug Development | 2019 |
| Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate | Clinical Pharmacology and Therapeutics | 2019 |
| A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs | Clinical Pharmacokinetics | 2019 |
| Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review | Journal of Pharmacy and Pharmacology | 2019 |
| Evaluation of the Drug Interaction Potential of Doravirine | Antimicrobial Agents and Chemotherapy | 2019 |
| Human mass balance, pharmacokinetics and metabolism of rovatirelin and identification of its metabolic enzymes | Xenobiotica | 2019 |
| Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects | Clinical Pharmacokinetics | 2019 |
| Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations | Scientific Reports | 2019 |
| Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer | Journal of Clinical Pharmacology | 2019 |
| EASL Clinical Practice Guidelines: Drug-induced liver injury | Journal of Hepatology | 2019 |
| Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers | Clinical and Translational Science | 2019 |
| Organotypic 3D HepaRG Liver Model for Assessment of Drug-Induced Cholestasis | Methods in Molecular Biology | 2019 |
| A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization | Clinical Pharmacology and Therapeutics | 2019 |
| Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations | Clinical Pharmacology and Therapeutics | 2019 |
| Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail | Journal of Personalized Medicine | 2019 |
| Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells | PLoS ONE | 2019 |
| The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis | Diabetes Research and Clinical Practice | 2019 |
| Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
| microRNA-206 modulates the hepatic expression of the organic anion-transporting polypeptide 1B1 | Liver International | 2019 |
| A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics | Cancer Chemotherapy and Pharmacology | 2019 |
| Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects | Clinical Pharmacokinetics | 2019 |
| Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review | Journal of Pharmacy and Pharmacology | 2019 |
| PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling | Clinical Pharmacology and Therapeutics | 2019 |
| A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide | Expert Opinion on Drug Metabolism and Toxicology | 2018 |
| Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach | Drug Metabolism and Disposition | 2018 |
| Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse | Archives of Toxicology | 2018 |
| In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines | Pharmaceutical Research | 2018 |
| Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel | Biochemical Pharmacology | 2018 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2018 |
| Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model | Pharmaceutics | 2017 |
| Drug–Drug Interaction Studies | | 2018 |
| Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects | Journal of Clinical Pharmacology | 2018 |
| Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy | British Journal of Clinical Pharmacology | 2018 |
| Mechanistic kinetic modeling generates system-independent P-glycoprotein mediated transport elementary rate constants for inhibition and, in combination with 3D SIM microscopy, elucidates the importance of microvilli morphology on P-glycoprotein mediated efflux activity | Expert Opinion on Drug Metabolism and Toxicology | 2018 |
| Sensitive and robust LC-MS/MS analysis of digoxin in human plasma through optimization of in-source adduct formation | Bioanalysis | 2018 |
| Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example | Biopharmaceutics and Drug Disposition | 2018 |
| A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis | Journal of Clinical Pharmacology | 2018 |
| Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers | Xenobiotica | 2018 |
| Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models | Journal of Applied Toxicology | 2018 |
| In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor | Clinical Pharmacology in Drug Development | 2018 |
| Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers | Paediatric Drugs | 2018 |
| In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
| Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling | Basic and Clinical Pharmacology and Toxicology | 2018 |
| Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies | Investigational New Drugs | 2018 |
| A phase I study to assess the mass balance, excretion, and pharmacokinetics of [C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors | Investigational New Drugs | 2018 |
| Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver | Drug Metabolism and Disposition | 2018 |
| In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes | Xenobiotica | 2018 |
| The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag | Xenobiotica | 2018 |
| Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
| Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? | European Journal of Clinical Pharmacology | 2018 |
| Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters | Journal of Clinical Pharmacology | 2018 |
| Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential | Clinical Pharmacokinetics | 2018 |
| Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development | Clinical and Translational Science | 2018 |
| In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics | European Journal of Clinical Pharmacology | 2018 |
| Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs | British Journal of Clinical Pharmacology | 2018 |
| Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What? | Clinical Pharmacology and Therapeutics | 2018 |
| Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions | British Journal of Clinical Pharmacology | 2018 |
| The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains | Journal of the American College of Cardiology | 2018 |
| Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature | Scientific Reports | 2017 |
| Role of ADME/PK in Drug Discovery, Safety Assessment, and Clinical Development | | 2017 |
| Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics | Drug Safety - Case Reports | 2017 |
| Validation of a total IC method which enables in vitro assessment of transporter inhibition under semi-physiological conditions | Xenobiotica | 2017 |
| A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine | Analytical and Bioanalytical Chemistry | 2017 |
| CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol | Food Chemistry | 2017 |
| Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver | Xenobiotica | 2017 |
| Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue | Biopharmaceutics and Drug Disposition | 2017 |
| An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation | Xenobiotica | 2017 |
| Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib | Xenobiotica | 2017 |
| Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens | AAPS Journal | 2017 |
| Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency | Clinical Pharmacology and Therapeutics | 2017 |
| A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects | European Journal of Clinical Pharmacology | 2017 |
| The Ussing Chamber Assay to Study Drug Metabolism and Transport in the Human Intestine | Current Protocols in Pharmacology | 2017 |
| The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation | Journal of Pharmacy and Pharmacology | 2017 |
| Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4 | Transplant Infectious Disease | 2017 |
| An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2 | Journal of Chromatography A | 2017 |
| Assessment of the Drug Interaction Potential of Unconjugated and GalNAc-Conjugated 2'-MOE-ASOs | Molecular Therapy - Nucleic Acids | 2017 |
| Pharmacovigilance: Work in Progress | Pharmaceutical Medicine | 2017 |
| Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A | Clinical Pharmacology and Therapeutics | 2017 |
| Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin | Drug Metabolism and Disposition | 2017 |
| Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions | Drugs | 2017 |
| Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers | Pharmaceutical Research | 2017 |
| The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation | Journal of Clinical Pharmacology | 2017 |
| The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance | Clinical Pharmacology and Therapeutics | 2017 |
| The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes | European Journal of Drug Metabolism and Pharmacokinetics | 2017 |
| Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP | Journal of Computer-Aided Molecular Design | 2017 |
| Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease | British Journal of Clinical Pharmacology | 2017 |
| Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro | Drug Metabolism and Disposition | 2017 |
| Translational Research: Preclinical to Healthy Volunteer to Patient | AAPS Advances in the Pharmaceutical Sciences Series | 2017 |
| Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients | Clinical Pharmacology and Therapeutics | 2017 |
| Tenapanor administration and the activity of the H -coupled transporter PepT1 in healthy volunteers | British Journal of Clinical Pharmacology | 2017 |
| Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport | Journal of Pharmaceutical Sciences | 2017 |
| Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults | Clinical Drug Investigation | 2017 |
| A call for a consortium for optimal management of drug-drug interactions in patient care | Clinical Pharmacology and Therapeutics | 2017 |
| Renal Drug Transporters and Drug Interactions | Clinical Pharmacokinetics | 2017 |
